Can a new drug cut seizure days in juvenile myoclonic epilepsy?

NCT ID NCT07723963

Not yet recruiting Disease control Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests whether an experimental drug called JZP926 can safely reduce the number of days people aged 10 and older experience myoclonic seizures—brief, shock-like jerks—due to juvenile myoclonic epilepsy. Participants are randomly assigned to receive either JZP926 or a placebo twice daily. The study aims to see if the drug lowers seizure frequency and improves daily functioning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called JZP926
What this could lead to: If it works, this could point toward a new treatment option for juvenile myoclonic epilepsy, potentially reducing seizure frequency.
What could go wrong: This is an early-to-mid-stage trial, so the drug may not prove effective or safe. Side effects are possible, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates